

# Hillard M Lazarus

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2950057/publications.pdf>

Version: 2024-02-01

363  
papers

14,503  
citations

31902

53  
h-index

23472

111  
g-index

404  
all docs

404  
docs citations

404  
times ranked

12631  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Defining the Intensity of Conditioning Regimens: Working Definitions. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1628-1633.  | 2.0  | 1,419     |
| 2  | Anthracycline Dose Intensification in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2009, 361, 1249-1259.   | 13.9 | 797       |
| 3  | Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 389-398.  | 2.0  | 745       |
| 4  | In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). <i>Blood</i> , 2008, 111, 1827-1833. | 0.6  | 702       |
| 5  | Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. <i>Blood</i> , 2005, 106, 3760-3767.  | 0.6  | 595       |
| 6  | Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission. <i>New England Journal of Medicine</i> , 1998, 339, 1649-1656.   | 13.9 | 569       |
| 7  | Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. <i>Blood</i> , 2016, 127, 2427-2438.  | 0.6  | 403       |
| 8  | Impact of immune modulation with anti-CD28 antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. <i>Blood</i> , 2011, 117, 6963-6970.  | 0.6  | 322       |
| 9  | Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. <i>Blood</i> , 2016, 127, 938-947.  | 0.6  | 246       |
| 10 | Prevalence of Hematopoietic Cell Transplant Survivors in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1498-1501.  | 2.0  | 210       |
| 11 | Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.   | 0.6  | 210       |
| 12 | Central nervous system toxicity of high-dose systemic cytosine arabinoside. <i>Cancer</i> , 1981, 48, 2577-2582.   | 2.0  | 209       |
| 13 | Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. <i>Blood</i> , 2006, 108, 465-472.   | 0.6  | 205       |
| 14 | Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. <i>Blood</i> , 2010, 116, 4077-4085.   | 0.6  | 188       |
| 15 | Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. <i>Blood</i> , 2010, 115, 1850-1857.   | 0.6  | 184       |
| 16 | A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. <i>Blood</i> , 2016, 128, 2561-2567.   | 0.6  | 174       |
| 17 | Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. <i>Blood</i> , 2016, 127, 496-502.  | 0.6  | 165       |
| 18 | Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3741-3749.   | 0.8  | 163       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Relationship between Bacterial Load, Species Virulence, and Transfusion Reaction with Transfusion of Bacterially Contaminated Platelets. <i>Clinical Infectious Diseases</i> , 2008, 46, 1214-1220.  | 2.9 | 156       |
| 20 | Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1046-1053.   | 2.0 | 133       |
| 21 | Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321. | 2.0 | 132       |
| 22 | Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer a phase I-II study. <i>Cancer</i> , 1983, 52, 1792-1802.   | 2.0 | 125       |
| 23 | Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. <i>Blood</i> , 2013, 121, 197-206.  | 0.6 | 123       |
| 24 | Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1729-1736.   | 2.0 | 119       |
| 25 | Antimicrobial Properties of Mesenchymal Stem Cells: Therapeutic Potential for Cystic Fibrosis Infection, and Treatment. <i>Stem Cells International</i> , 2016, 2016, 1-12.  | 1.2 | 117       |
| 26 | Allogeneic transplantation provides durable remission in a subset of <scp>DLBCL</scp> patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248.   | 1.2 | 115       |
| 27 | CAR-T “ and a side order of IgG, to go? “ Immunoglobulin replacement in patients receiving CAR-T cell therapy. <i>Blood Reviews</i> , 2019, 38, 100596.  | 2.8 | 109       |
| 28 | Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.  | 2.0 | 105       |
| 29 | Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. <i>Journal of Clinical Oncology</i> , 2016, 34, 3544-3553.  | 0.8 | 99        |
| 30 | Salvage Second Hematopoietic Cell Transplantation in Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 760-766.  | 2.0 | 98        |
| 31 | Intravenous immunoglobulin: Appropriate indications and uses in hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 117-130.  | 2.0 | 96        |
| 32 | Randomized Cross-Over Trial of Progenitor-Cell Mobilization: High-Dose Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor (G-CSF) Versus Granulocyte-Macrophage Colony-Stimulating Factor Plus G-CSF. <i>Journal of Clinical Oncology</i> , 2000, 18, 1824-1830.                                  | 0.8 | 91        |
| 33 | Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.  | 2.5 | 89        |
| 34 | A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 35-45.  | 2.0 | 88        |
| 35 | Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 501-511.   | 1.4 | 86        |
| 36 | Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 3291-3305.  | 0.6 | 85        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. <i>Transfusion</i> , 2006, 46, 719-730.  | 0.8 | 84        |
| 38 | Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2012, 2, 1004-1023.  | 7.7 | 80        |
| 39 | Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1796-1803.   | 2.0 | 73        |
| 40 | Pediatricâ€inspired therapy compared to allografting for <scp>P</scp>hiladelphia chromosomeâ€negative adult ALL in first complete remission. <i>American Journal of Hematology</i> , 2016, 91, 322-329.                                       | 2.0 | 72        |
| 41 | Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1636-1645.   | 2.0 | 71        |
| 42 | Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.                                      | 2.0 | 71        |
| 43 | Lowering the Prophylactic Platelet Transfusion Threshold: a Prospective Analysis. <i>Leukemia and Lymphoma</i> , 2001, 41, 67-76.   | 0.6 | 70        |
| 44 | A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 428-432.e2.   | 0.2 | 68        |
| 45 | Allogeneic hematopoietic cell transplantation; the current renaissance. <i>Blood Reviews</i> , 2019, 34, 34-44.   | 2.8 | 67        |
| 46 | Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 335-341.   | 2.0 | 64        |
| 47 | Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.  | 2.5 | 63        |
| 48 | Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. <i>Blood Reviews</i> , 2021, 47, 100773.  | 2.8 | 63        |
| 49 | Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. <i>Cancer</i> , 1994, 73, 1716-1720.   | 2.0 | 61        |
| 50 | Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.   | 2.0 | 61        |
| 51 | Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495. | 1.3 | 61        |
| 52 | Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation. <i>Cancer</i> , 1982, 49, 1789-1795.  | 2.0 | 60        |
| 53 | Molecular classification improves risk assessment in adult <i>BCR-ABL1â€negative B-ALL. <i>Blood</i> , 2021, 138, 948-958.   | 0.6 | 59        |
| 54 | Incidence, Risk Factors for and Outcomes of Transplantâ€Associated Thrombotic Microangiopathy. <i>British Journal of Haematology</i> , 2020, 189, 1171-1181.   | 1.2 | 58        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Phase 1 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 720-728. | 2.0 | 56        |
| 56 | Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2091-2099.                            | 2.0 | 55        |
| 57 | The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. <i>Haematologica</i> , 2013, 98, 945-952.   | 1.7 | 54        |
| 58 | Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 861-873.   | 2.0 | 53        |
| 59 | The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. <i>Haematologica</i> , 2016, 101, 1426-1433.   | 1.7 | 53        |
| 60 | Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2020, 190, 822-836.  | 1.2 | 53        |
| 61 | Topical fluoroquinolones: Antimicrobial activity and <i>in vitro</i> corneal epithelial toxicity. <i>Current Eye Research</i> , 1991, 10, 557-563.   | 0.7 | 51        |
| 62 | Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.   | 1.7 | 51        |
| 63 | Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1777-1784.   | 2.0 | 50        |
| 64 | Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 151-158.                                | 2.0 | 49        |
| 65 | An <i>in vitro</i> Analysis of Aminoglycoside Corneal Epithelial Toxicity. <i>Current Eye Research</i> , 1989, 8, 299-304.   | 0.7 | 48        |
| 66 | The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1746-1753.                                     | 2.0 | 48        |
| 67 | Midostaurin: an emerging treatment for acute myeloid leukemia patients. <i>Journal of Blood Medicine</i> , 2016, 7, 73.  | 0.7 | 48        |
| 68 | Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1254-1265.   | 1.3 | 47        |
| 69 | Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.   | 2.0 | 47        |
| 70 | Cutaneous Malignant Neoplasms in Hematopoietic Cell Transplant Recipients. <i>JAMA Dermatology</i> , 2015, 151, 775.   | 2.0 | 46        |
| 71 | Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 42-49.  | 2.0 | 46        |
| 72 | Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016, 122, 3005-3014.  | 2.0 | 45        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center For International Blood & Marrow Transplant Research (CIBMTR). <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1323-1333. | 2.0 | 44        |
| 74 | Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large B-cell lymphoma. <i>Cancer</i> , 2018, 124, 816-825.  | 2.0 | 44        |
| 75 | Vascular graft-associated complement activation and leukocyte adhesion in an artificial circulation. <i>Journal of Biomedical Materials Research Part B</i> , 1987, 21, 379-397.   | 3.0 | 43        |
| 76 | Survival Improvements in Adolescents and Young Adults after Myeloablative Allogeneic Transplantation for Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 829-836.   | 2.0 | 43        |
| 77 | Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1819-1827.   | 2.0 | 43        |
| 78 | Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. <i>Haematologica</i> , 2017, 102, 1823-1832.  | 1.7 | 43        |
| 79 | Spontaneous Autologous Graft-versus-Host Disease in Plasma Cell Myeloma Autograft Recipients: Flow Cytometric Analysis of Hematopoietic Progenitor Cell Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 970-978.  | 2.0 | 42        |
| 80 | Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1543-1551.   | 2.0 | 42        |
| 81 | Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 245-261.  | 1.1 | 42        |
| 82 | Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2086-2090.   | 2.0 | 42        |
| 83 | Reticulocyte quantification by flow cytometry, image analysis, and manual counting. <i>Cytometry</i> , 1992, 13, 853-862.  | 1.8 | 40        |
| 84 | Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1418-1425.  | 2.0 | 40        |
| 85 | Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. <i>Blood Reviews</i> , 2018, 32, 106-115.  | 2.8 | 40        |
| 86 | Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 362-368.  | 2.0 | 40        |
| 87 | Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.   | 2.0 | 39        |
| 88 | Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. <i>JAMA Oncology</i> , 2020, 6, 1011.  | 3.4 | 39        |
| 89 | Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1327-1334.  | 2.0 | 38        |
| 90 | Allotransplantation for Patients Age <math>\geq 40</math> Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.  | 2.0 | 37        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019, 3, 3123-3131.  | 2.5 | 37        |
| 92  | Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2922-2936.   | 2.5 | 35        |
| 93  | Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.  | 2.5 | 35        |
| 94  | Multiple myeloma in young men clinical course and electron microscopic studies of bone marrow plasma cells. <i>Cancer</i> , 1980, 46, 1397-1400.  | 2.0 | 34        |
| 95  | Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.  | 2.0 | 34        |
| 96  | Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 983-992.   | 2.5 | 34        |
| 97  | Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 556-568.  | 0.6 | 34        |
| 98  | Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.                  | 2.0 | 33        |
| 99  | Avascular Necrosis of Bone after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 587-592.   | 2.0 | 33        |
| 100 | New Cancers after Autotransplantations for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 738-745.  | 2.0 | 33        |
| 101 | Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.  | 2.0 | 33        |
| 102 | Rapid Transport and Infusion of Hematopoietic Cells Is Associated with Improved Outcome after Myeloablative Therapy and Unrelated Donor Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 589-596.                       | 2.0 | 32        |
| 103 | Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. <i>JAMA Oncology</i> , 2022, 8, 404. | 3.4 | 32        |
| 104 | Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 478-485.     | 2.0 | 31        |
| 105 | Incidence and outcome of overt gastrointestinal bleeding in patients undergoing bone marrow transplantation. <i>Digestive Diseases and Sciences</i> , 1996, 41, 598-603.  | 1.1 | 29        |
| 106 | Comparison of Twin and Autologous Transplants for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1118-1124.   | 2.0 | 28        |
| 107 | Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1134-1140.  | 2.0 | 27        |
| 108 | Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018, 2, 933-940.   | 2.5 | 27        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.  | 3.3 | 27        |
| 110 | Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?. <i>Frontiers in Immunology</i> , 2021, 12, 706186.  | 2.2 | 27        |
| 111 | Race and Ethnicity Influences Collection of Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Progenitor Cells from Unrelated Donors, a Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 165-171.                                   | 2.0 | 26        |
| 112 | The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 507-516.  | 0.6 | 26        |
| 113 | Kinetics of Erythropoiesis after Bone Marrow Transplantation. <i>American Journal of Clinical Pathology</i> , 1992, 97, 574-583.   | 0.4 | 25        |
| 114 | Clinical Trial: Hematopoietic Progenitor Cell Transplantation in Breast Cancer: Current Status and Future Directions. <i>Cancer Investigation</i> , 1998, 16, 102-126.   | 0.6 | 24        |
| 115 | Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an eastern cooperative oncology group trial (E4995). <i>Leukemia and Lymphoma</i> , 2005, 46, 55-61.  | 0.6 | 24        |
| 116 | Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338. | 1.7 | 23        |
| 117 | Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making. <i>Expert Review of Hematology</i> , 2017, 10, 563-574.   | 1.0 | 22        |
| 118 | Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. <i>Transplant Infectious Disease</i> , 2019, 21, e13145.  | 0.7 | 22        |
| 119 | Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. <i>Blood Advances</i> , 2018, 2, 1198-1206.  | 2.5 | 21        |
| 120 | Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2398-2407.  | 2.0 | 21        |
| 121 | A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. <i>American Journal of Hematology</i> , 2019, 94, 111-117.   | 2.0 | 21        |
| 122 | Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.   | 2.0 | 21        |
| 123 | Cyclic parenteral nutrition during bone marrow transplantation in children. <i>Cancer</i> , 1983, 51, 1563-1570.   | 2.0 | 20        |
| 124 | High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later. <i>Journal of Clinical Oncology</i> , 2008, 26, 2240-2243.   | 0.8 | 19        |
| 125 | Notch2 blockade enhances hematopoietic stem cell mobilization and homing. <i>Haematologica</i> , 2017, 102, 1785-1795.   | 1.7 | 19        |
| 126 | Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.   | 2.0 | 19        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Anti-cancer vaccine therapy for hematologic malignancies: An evolving era. <i>Blood Reviews</i> , 2018, 32, 312-325.  | 2.8 | 19        |
| 128 | Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. <i>Bone Marrow Transplantation</i> , 2019, 54, 1354-1360.   | 1.3 | 19        |
| 129 | Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study. <i>Blood</i> , 2019, 134, 115-115.  | 0.6 | 19        |
| 130 | Double Umbilical Cord Blood Transplantation: Relevance of Persistent Mixed-Unit Chimerism. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 612-619.  | 2.0 | 18        |
| 131 | Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 683-688.   | 2.0 | 18        |
| 132 | A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 226-233.e1.   | 0.2 | 18        |
| 133 | Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.   | 2.5 | 18        |
| 134 | Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 48.e1-48.e10.  | 0.6 | 18        |
| 135 | Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. <i>Leukemia Research</i> , 2017, 59, 55-64.   | 0.4 | 17        |
| 136 | Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization. <i>Blood Reviews</i> , 2021, 47, 100771.   | 2.8 | 17        |
| 137 | Outcomes of rituximab+BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.   | 2.0 | 17        |
| 138 | Bacterial contamination and septic transfusion reaction rates associated with platelet components before and after introduction of primary culture: experience at a US Academic Medical Center 1991 through 2017. <i>Transfusion</i> , 2020, 60, 974-985.   | 0.8 | 16        |
| 139 | Peripheral neuropathy in hematologic malignancies – Past, present and future. <i>Blood Reviews</i> , 2020, 43, 100653.  | 2.8 | 16        |
| 140 | Fluctuation of serum phenytoin concentrations during autologous bone marrow transplant for primary central nervous system tumors. <i>Journal of Neuro-Oncology</i> , 1992, 12, 25-32.   | 1.4 | 15        |
| 141 | Maximizing anthracycline tolerability in hematologic malignancies: Treat to each heart's content. <i>Blood Reviews</i> , 2016, 30, 169-178.   | 2.8 | 15        |
| 142 | G-CSF and GM-CSF Are Different. Which One Is Better for COVID-19?. <i>Acta Haematologica</i> , 2021, 144, 355-359.  | 0.7 | 15        |
| 143 | Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9. | 0.6 | 15        |
| 144 | African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.   | 2.0 | 15        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12.   | 0.6 | 15        |
| 146 | Infusion of High Doses of Undiluted Etoposide Through Central Venous Catheters During Preparation for Bone Marrow Transplantation. <i>Cancer Investigation</i> , 1990, 8, 13-16.   | 0.6 | 14        |
| 147 | Bone Marrow Transplantation in Low-Grade Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1995, 17, 199-210.   | 0.6 | 14        |
| 148 | The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1251-1257.  | 2.0 | 14        |
| 149 | Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 520-527.   | 2.0 | 14        |
| 150 | Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. <i>Cancer</i> , 2017, 123, 2035-2042. | 2.0 | 14        |
| 151 | Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1424-1431.  | 2.0 | 14        |
| 152 | Comparison of outcomes of HCT in blast phase of <i>t(9;22) BCR-ABL1</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757.   | 2.5 | 14        |
| 153 | A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.  | 2.0 | 14        |
| 154 | Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. <i>Blood Advances</i> , 2020, 4, 2084-2094.   | 2.5 | 14        |
| 155 | A CIBMTR Prognostic Model for Progression-Free Survival (PFS) After Autologous Hematopoietic Cell Transplantation (AHCT) for Relapsed or Refractory Hodgkin Lymphoma (HL). <i>Blood</i> , 2011, 118, 499-499.  | 0.6 | 14        |
| 156 | Renal dysfunction during high-dose cisplatin therapy and autologous hematopoietic stem cell transplantation: Effect of aminoglycoside therapy. <i>American Journal of Medicine</i> , 1993, 94, 497-504.  | 0.6 | 13        |
| 157 | Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1815-1822.                                     | 2.0 | 13        |
| 158 | Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. <i>Blood Advances</i> , 2019, 3, 2525-2536.  | 2.5 | 13        |
| 159 | Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 553-561.               | 2.0 | 13        |
| 160 | The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1137-1143.                       | 2.0 | 13        |
| 161 | Can we prevent or treat graft-versus-host disease with cellular-therapy?. <i>Blood Reviews</i> , 2020, 43, 100669.   | 2.8 | 13        |
| 162 | Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 264.e1-264.e7.        | 0.6 | 13        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 410-422.  | 0.6 | 13        |
| 164 | Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial. <i>Blood</i> , 2010, 116, 169-169.   | 0.6 | 13        |
| 165 | High-dose cytosine arabinoside in the treatment of refractory acute nonlymphocytic leukemia in adults: Results of two six-day regimens. <i>Medical and Pediatric Oncology</i> , 1982, 10, 229-233.  | 1.0 | 12        |
| 166 | Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1830-1838. | 2.0 | 12        |
| 167 | Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes. <i>British Journal of Haematology</i> , 2016, 173, 404-412.  | 1.2 | 12        |
| 168 | Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1099-1106.   | 2.0 | 12        |
| 169 | Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. <i>Cancer</i> , 2021, 127, 609-618.  | 2.0 | 12        |
| 170 | Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation. <i>British Journal of Haematology</i> , 2021, 194, 145-157.                                  | 1.2 | 12        |
| 171 | CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials. <i>Blood Advances</i> , 2021, 5, 4560-4568.   | 2.5 | 12        |
| 172 | New strategies for the evaluation of the nadir bone marrow following induction in acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2013, 20, 93-99.   | 1.2 | 11        |
| 173 | Neoplastic and non-neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance. <i>Clinical Transplantation</i> , 2015, 29, 851-857.  | 0.8 | 11        |
| 174 | Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.          | 2.0 | 11        |
| 175 | The pharmacologic management of multiple myeloma in older adults. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 887-902.   | 0.9 | 11        |
| 176 | Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. <i>Blood Advances</i> , 2020, 4, 706-716.  | 2.5 | 11        |
| 177 | Promising role for mesenchymal stromal cells in coronavirus infectious disease-19 (COVID-19)-related severe acute respiratory syndrome?. <i>Blood Reviews</i> , 2021, 46, 100742.   | 2.8 | 11        |
| 178 | Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10.  | 0.6 | 11        |
| 179 | Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 310-320.  | 0.6 | 11        |
| 180 | Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and Tj ETQq0 0 Q,rgBT /Overlock 10 Tj 23-27.  | 2.8 | 10        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 181 | Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1320-1326. | 2.0 | 10        |
| 182 | Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.  | 3.2 | 10        |
| 183 | Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 194, 309-318.  | 1.2 | 10        |
| 184 | Invasive fungal disease and the immunocompromised host including allogeneic hematopoietic cell transplant recipients: Improved understanding and new strategic approach with sargramostim. <i>Clinical Immunology</i> , 2021, 228, 108731.  | 1.4 | 10        |
| 185 | Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 679.e1-679.e8.  | 0.6 | 10        |
| 186 | A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 250.e1-250.e8.   | 0.6 | 10        |
| 187 | The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. <i>Haematologica</i> , 2023, 108, 150-160.                          | 1.7 | 10        |
| 188 | Autologous hematopoietic cell transplantation for adult acute myeloid leukemia: An obsolete or resurfacing concept?. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 327-332.   | 0.7 | 9         |
| 189 | At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial. <i>British Journal of Haematology</i> , 2020, 191, 37-43.  | 1.2 | 9         |
| 190 | Risk Factors for Keratinocyte Carcinoma in Recipients of Allogeneic Hematopoietic Cell Transplants. <i>JAMA Dermatology</i> , 2020, 156, 631.   | 2.0 | 9         |
| 191 | Is G-CSF Dangerous in COVID-19: Why Not Use GM-CSF?. <i>Acta Haematologica</i> , 2021, 144, 350-351.  | 0.7 | 9         |
| 192 | Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 1309-1309.   | 0.6 | 9         |
| 193 | Antimicrobial activity and in vitro corneal epithelial toxicity of antimicrobial agents for Gram-positive corneal pathogens. <i>Current Eye Research</i> , 1993, 12, 603-608.   | 0.7 | 8         |
| 194 | Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 327.   | 1.3 | 8         |
| 195 | Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma-specific venous thrombosis prediction models. <i>American Journal of Hematology</i> , 2020, 95, 918-926.  | 2.0 | 8         |
| 196 | DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Seminars in Hematology</i> , 2021, 58, 45-55.                 | 1.8 | 8         |
| 197 | Impact of Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Grade-III Follicular (FL-III) and Diffuse Large B-Cell Lymphomas (DLBCL): A CIBMTR Analysis. <i>Blood</i> , 2012, 120, 473-473.                            | 0.6 | 8         |
| 198 | Survival Improvements Following Myeloablative Allogeneic Hematopoietic Cell Transplantation For Acute Lymphoblastic Leukemia In Adolescents and Young Adults Have Been Comparable To Younger Children: A Study From The CIBMTR. <i>Blood</i> , 2013, 122, 554-554.                  | 0.6 | 8         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 199 | When, how, and what cell source for hematopoietic cell transplantation in first complete remission adult acute lymphoblastic leukemia?. Hematology American Society of Hematology Education Program, 2012, 2012, 382-8.  | 0.9 | 8         |
| 200 | Acute leukemia in adults: novel allogeneic transplant strategies. Hematology, 2012, 17, s47-s51.   | 0.7 | 7         |
| 201 | Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients. Biology of Blood and Marrow Transplantation, 2015, 21, 1926-1931.  | 2.0 | 7         |
| 202 | Early Passage Dependence of Mesenchymal Stem Cell Mechanics Influences Cellular Invasion and Migration. Annals of Biomedical Engineering, 2016, 44, 2123-2131.   | 1.3 | 7         |
| 203 | Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876528.  | 0.5 | 7         |
| 204 | Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 945-955.   | 2.0 | 7         |
| 205 | Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. Biology of Blood and Marrow Transplantation, 2018, 24, 175-184.   | 2.0 | 7         |
| 206 | Microtransplantation for Acute Myeloid Leukemia. JAMA Oncology, 2020, 6, 1614.   | 3.4 | 7         |
| 207 | Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. Bone Marrow Transplantation, 2020, 55, 2121-2131.   | 1.3 | 7         |
| 208 | The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 1747-1756.                      | 2.0 | 7         |
| 209 | Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults Age ≥60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial. Blood, 2016, 128, 339-339. | 0.6 | 7         |
| 210 | Favorable outcome to glucocorticoid therapy for engraftment syndrome in pediatric autologous hematopoietic cell transplant. Pediatric Transplantation, 2016, 20, 297-302.  | 0.5 | 6         |
| 211 | Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2108-2117.   | 1.3 | 6         |
| 212 | Outcome of 1,229 Adult Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia (B-ALL) Patients (pts) From the International UKALLXII/E2993 Trial: No Difference in Results Between B Cell Immunophenotypic Subgroups. Blood, 2010, 116, 524-524.  | 0.6 | 6         |
| 213 | Superior Survival after Autologous vs. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Diffuse Large B-Cell Lymphoma (DLBCL) Not Explained by Differences in Chemosensitivity.. Blood, 2006, 108, 3021-3021.  | 0.6 | 6         |
| 214 | Improving Survival in Acute Myeloid Leukemia: Pick the Best Subjects?. Journal of Clinical Oncology, 2013, 31, 3854-3856.  | 0.8 | 5         |
| 215 | Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia. Pediatric Transplantation, 2017, 21, e12870.   | 0.5 | 5         |
| 216 | Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. Journal of Cancer, 2017, 8, 1009-1017.   | 1.2 | 5         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 217 | Consolidation in AML: Abundant opinion and much unknown. <i>Blood Reviews</i> , 2022, 51, 100873.   | 2.8 | 5         |
| 218 | Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>&lt;i&gt;KMT2A&lt;/i&gt;-rearranged AML. <i>Blood Advances</i>, 2022, 6, 828-847.</i>  | 2.5 | 5         |
| 219 | A phase I study of MGMT-P140K transfected hematopoietic progenitor cells (HPC) combined with TMZ/O6BG dose escalation for newly diagnosed, MGMT unmethylated glioblastoma: Tolerance and evidence of survival benefit.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2062-2062.  | 0.8 | 5         |
| 220 | Development of a Functional Biomarker for Use in Cell-Based Therapy Studies in Seropositive Rheumatoid Arthritis. <i>Stem Cells Translational Medicine</i> , 2016, 5, 628-631.  | 1.6 | 4         |
| 221 | SAT0010â€¦FUNCTIONAL BIOMARKER DEVELOPMENT FOR CELL-BASED THERAPY IN RHEUMATOID ARTHRITIS. , 2019, , .  |     | 4         |
| 222 | Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900. <i>Haematologica</i> , 2019, 104, e147-e150.  | 1.7 | 4         |
| 223 | A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2191-2199.  | 0.6 | 4         |
| 224 | Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1210-1217.  | 2.0 | 4         |
| 225 | Role of molecularly-cloned hematopoietic growth factors after acute high-dose radiation exposures. <i>Journal of Radiological Protection</i> , 2021, 41, S478-S489.   | 0.6 | 4         |
| 226 | Granulocyte transfusions in haematopoietic cell transplants and leukaemia: the phoenix or beating a dead horse?. <i>Bone Marrow Transplantation</i> , 2021, 56, 2046-2049.  | 1.3 | 4         |
| 227 | Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 993.e1-993.e8.  | 0.6 | 4         |
| 228 | Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 31-37.   | 1.3 | 4         |
| 229 | Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2021, 138, 3880-3880.   | 0.6 | 4         |
| 230 | Human Multipotent Adult Progenitor Cells Effectively Reduce Graft-vs-Host Disease While Preserving Graft-Vs-Leukemia Activity. <i>Stem Cells</i> , 2021, 39, 1506-1519.   | 1.4 | 4         |
| 231 | The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 603.e1-603.e7.   | 0.6 | 4         |
| 232 | Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. <i>Transfusion</i> , 2020, 60, 1867-1872.   | 0.8 | 3         |
| 233 | New cancer therapies. Are haematopoietic cell transplants a dead duck?. <i>Bone Marrow Transplantation</i> , 2021, 56, 1086-1089.   | 1.3 | 3         |
| 234 | Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [lomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial. <i>Blood</i> , 2019, 134, 5642-5642. | 0.6 | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 235 | Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered. <i>Blood</i> , 2020, 136, 42-44.   | 0.6 | 3         |
| 236 | Allogeneic Hematopoietic Cell Transplantation (AHCT) for Primary Cutaneous T Cell Lymphoma (CTCL): a Center for International Blood and Marrow Transplant Research (CIBMTR) Review. <i>Blood</i> , 2010, 116, 364-364.   | 0.6 | 3         |
| 237 | Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL): Results From the International MRC/ECOG Trial. <i>Blood</i> , 2010, 116, 493-493.   | 0.6 | 3         |
| 238 | Increased Risk of Venous Thromboembolism in Primary Central Nervous System Lymphoma Patients Undergoing Therapy. <i>Blood</i> , 2014, 124, 5431-5431.  | 0.6 | 3         |
| 239 | Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 679-679.  | 0.6 | 3         |
| 240 | Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.   | 0.6 | 3         |
| 241 | Immunophenotypic and molecular comparison between allogeneic and autologous graft-versus-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1087-1091.  | 0.7 | 2         |
| 242 | Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1928-1935.   | 2.0 | 2         |
| 243 | The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). <i>Leukemia Research</i> , 2019, 78, 29-33.  | 0.4 | 2         |
| 244 | Does a durian smell like a rose? The dangers of jargon. <i>Bone Marrow Transplantation</i> , 2020, 55, 280-282.  | 1.3 | 2         |
| 245 | Evaluation of Tumor Vaccine Generation in a Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant (AutoHCT) Followed By Lenalidomide Maintenance for Multiple Myeloma (MM) with or without Vaccination with Dendritic Cell/ Myeloma Fusions (DC/MM fusion) Tj ETQq1 1 0.784314 rgBT/Overlook   | 1.0 | 2         |
| 246 | Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S32-S33. | 2.0 | 2         |
| 247 | Casting a wider protective net: Anti-infective vaccine strategies for patients with hematologic malignancy and blood and marrow transplantation. <i>Blood Reviews</i> , 2021, 47, 100779.  | 2.8 | 2         |
| 248 | Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 503.e1-503.e8.  | 0.6 | 2         |
| 249 | High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 30-31.  | 0.6 | 2         |
| 250 | Relationship of Race/Ethnicity and Survival After Single Umbilical Cord Blood Transplantation. <i>Blood</i> , 2010, 116, 224-224.  | 0.6 | 2         |
| 251 | Spleen Status and Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation (HCT).. <i>Blood</i> , 2010, 116, 3486-3486.  | 0.6 | 2         |
| 252 | R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission. <i>Blood</i> , 2012, 120, 676-676.  | 0.6 | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 253 | Phase I study of midostaurin and azacitidine in relapsed and elderly AML. Journal of Clinical Oncology, 2013, 31, 7058-7058.   | 0.8 | 2         |
| 254 | Optimization of Human Mesenchymal Stem Cells for Rheumatoid Arthritis: Implications for Improved Therapeutic Outcomes. ACR Open Rheumatology, 2021, , .  | 0.9 | 2         |
| 255 | A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplantation, 2022, 57, 295-298.   | 1.3 | 2         |
| 256 | Diagnosis and treatment of graft-versus-host disease. , 2013, , 311-329.   |     | 1         |
| 257 | Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 73-82.  | 0.2 | 1         |
| 258 | Treatment-related mortality following autologous hematopoietic stem cell transplantation is unaffected by timing of G-CSF administration. Bone Marrow Transplantation, 2020, 55, 1697-1700.  | 1.3 | 1         |
| 259 | Liaisons Dangereuses? new drugs, physicians and the drug industry. Bone Marrow Transplantation, 2021, 56, 299-302.   | 1.3 | 1         |
| 260 | Mesenchymal Stromal Cells: Impact on Hematopoietic Cell Transplantation. , 2021, , 859-870.  |     | 1         |
| 261 | The impact of cult behavior on haematopoietic cell transplant practices: believers and non-believers. Bone Marrow Transplantation, 2021, , .   | 1.3 | 1         |
| 262 | Prospective, Multi-Center, Phase I Clinical Trial of PLX-R18 Placental Expanded Adherent Stromal Cells in Subjects with Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation. Blood, 2018, 132, 3379-3379.   | 0.6 | 1         |
| 263 | Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood, 2008, 112, 3314-3314.   | 0.6 | 1         |
| 264 | Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHCT) for Patients Relapsing after Autologous Stem Cell Transplantation (autoHCT) for B Cell Non-Hodgkin Lymphoma (NHL). Blood, 2008, 112, 459-459.   | 0.6 | 1         |
| 265 | Second Unrelated Donor (URD) Transplant as a Rescue Strategy for 122 Patients with Primary Non Engraftment: Results from the CIBMTR. Blood, 2008, 112, 794-794.  | 0.6 | 1         |
| 266 | â€œSecondary MGUSâ€•After High-Dose Melphalan and Autologous Hematopoietic Progenitor Cell Transplantation In Multiple Myeloma: A Matter of Undetermined Significance.. Blood, 2010, 116, 1296-1296.   | 0.6 | 1         |
| 267 | Impact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignanciesimpact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies. Blood, 2010, 116, 2305-2305. | 0.6 | 1         |
| 268 | The Role of Hematopoietic Cell Transplantation (HCT) for Burkitt Lymphoma: a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR). Blood, 2010, 116, 2390-2390.  | 0.6 | 1         |
| 269 | Is There a Role for ASCT in Patients with Desmoplastic Small Round Cell Tumor of the Peritoneum?. Blood, 2011, 118, 3092-3092.   | 0.6 | 1         |
| 270 | Older Age, Use Of Myeloablative Regimens For Malignant Diseases and Chronic Graft-Versus-Host Disease Are Risk Factors For Avascular Necrosis Of Bone After Allogeneic Hematopoietic Cell Transplantation In Children and Adolescents. Blood, 2013, 122, 917-917.  | 0.6 | 1         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 271 | Low Dose Antithymocyte Globulin (ATG) for Graft-Versus-Host Disease (GVHD) Prophylaxis. <i>Blood</i> , 2016, 128, 5788-5788.  | 0.6 | 1         |
| 272 | Historical perspective and a glance into the antibody-based conditioning regimens: A new era in the horizon?. <i>Blood Reviews</i> , 2022, 52, 100892.  | 2.8 | 1         |
| 273 | Rapid Transport and Infusion of Hematopoietic Stem Cells Can Improve Outcome after Unrelated Donor Transplant.. <i>Blood</i> , 2007, 110, 3063-3063.  | 0.6 | 1         |
| 274 | Effect of Graft Source and Transplant Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Mantle Cell Lymphoma (MCL): A CIBMTR Analysis. <i>Blood</i> , 2012, 120, 815-815.  | 0.6 | 1         |
| 275 | Cutaneous complications in hematopoietic cell transplant recipients: Impact of biopsy on patient management.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7036-7036.  | 0.8 | 1         |
| 276 | Charlson Comorbidity Index (CCI) and Hematopoietic Cell Transplantation Specific-Comorbidity Index (HCT-CI) Do Not Predict Transplant Related Mortality (TRM) and Post-Transplant Outcomes In Young Patients Undergoing Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation. <i>Blood</i> , 2013, 122, 4582-4582. | 0.6 | 1         |
| 277 | Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children. <i>Blood</i> , 2016, 128, 664-664.   | 0.6 | 1         |
| 278 | A Phase I Dose Finding Trial of Eltrombopag during Consolidation Therapy in Adults with Acute Myeloid Leukemia Employing a Unique Dosing Design: PrE0901, a Precog Study. <i>Blood</i> , 2016, 128, 4053-4053.  | 0.6 | 1         |
| 279 | Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study. <i>Blood</i> , 2021, 138, 413-413.  | 0.6 | 1         |
| 280 | Safety and Demonstrated Efficacy of Placenta-Derived Cell Therapy PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation: A Phase I International Multi-Center Study. <i>Blood</i> , 2020, 136, 24-25.   | 0.6 | 1         |
| 281 | Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?. <i>British Journal of Haematology</i> , 2022, 197, 326-338.  | 1.2 | 1         |
| 282 | Protein Biomarkers in Monocytes and CD4 Lymphocytes for Predicting Lithium Treatment Response of Bipolar Disorder: a Feasibility Study with Tyramine-Based Signal-Amplified Flow Cytometry.. <i>Psychopharmacology Bulletin</i> , 2022, 52, 8-35.   | 0.0 | 1         |
| 283 | HLA-testing and laboratory medicine. , 0, , 495-510.  |     | 0         |
| 284 | Basic science. , 0, , 3-20.   |     | 0         |
| 285 | Therapeutic decision making in BMT/SCT for acute myeloid leukemia. , 0, , 23-40.  |     | 0         |
| 286 | Therapeutic decision making in BMT/SCT for acute lymphoblastic leukemia. , 0, , 41-56.  |     | 0         |
| 287 | Therapeutic decision making in BMT/SCT for chronic myeloid leukemia and other myeloproliferative syndromes. , 0, , 57-70.   |     | 0         |
| 288 | Therapeutic decision making in BMT/SCT for chronic lymphatic leukemia. , 0, , 71-84.  |     | 0         |

| #   | ARTICLE   | IF | CITATIONS |
|-----|---|----|-----------|
| 289 | Therapeutic decision making in BMT/SCT for myelodysplasia. , 0 , 85-98.   |    | 0         |
| 290 | Therapeutic decision making in BMT/SCT for non-Hodgkin lymphoma. , 0 , 99-126.  |    | 0         |
| 291 | Therapeutic decision making in BMT/SCT for Hodgkin lymphoma. , 0 , 127-138.   |    | 0         |
| 292 | Therapeutic decision making in hematopoietic stem cell transplantation for multiple myeloma. , 0 , 139-156.           |    | 0         |
| 293 | Therapeutic decision making in BMT/SCT for amyloidosis. , 0 , 157-162.  |    | 0         |
| 294 | Therapeutic decision making in stem cell transplantation for breast cancer. , 0 , 165-168.                            |    | 0         |
| 295 | Therapeutic decision making in BMT/SCT for nonseminomatous germ cell tumor of testis (NSGCT). , 0 , 169-176.          |    | 0         |
| 296 | Therapeutic decision making in BMT/SCT for renal cell cancer. , 0 , 177-188.  |    | 0         |
| 297 | Therapeutic decision making in BMT/SCT for soft tissue sarcomas. , 0 , 189-194.                                       |    | 0         |
| 298 | Therapeutic decision making in BMT/SCT for severe aplastic anemia. , 0 , 197-204.                                     |    | 0         |
| 299 | Therapeutic decision making in BMT/SCT for congenital immunodeficiencies. , 0 , 205-214.                              |    | 0         |
| 300 | Therapeutic decision making in BMT/SCT for hemoglobinopathies. , 0 , 215-226.   |    | 0         |
| 301 | Therapeutic decision making in BMT/SCT for autoimmune disorders. , 0 , 227-232.                                       |    | 0         |
| 302 | Practical aspects and procedures, including conditioning protocols and haploidentical transplantation. , 0 , 235-300. |    | 0         |
| 303 | Umbilical cord blood as alternative allogeneic graft source: clinical banking and transplant outcomes. , 0 , 301-310. |    | 0         |
| 304 | Pathobiology of graft-versus-host disease. , 0 , 313-330.   |    | 0         |
| 305 | Diagnosis and treatment of graft-versus-host-disease. , 0 , 331-356.  |    | 0         |
| 306 | Management and prophylaxis of infections after BMT/SCT. , 0 , 357-378.  |    | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 307 | Organ-related and miscellaneous complications. , 0 , 379-428.  |     | 0         |
| 308 | The BMT/SCT pharmacopoeia. , 0 , 431-492.  |     | 0         |
| 309 | Reptilase for ANLL with DIC. Scandinavian Journal of Haematology, 1986, 36, 411-412.                                     | 0.0 | 0         |
| 310 | Acute Leukemia. , 2011, , 235-250.   |     | 0         |
| 311 | The BMT/SCT pharmacopoeia. , 0 , 411-508.  |     | 0         |
| 312 | Hematopoietic cell transplantation for non-Hodgkin lymphoma. , 0 , 90-112.   |     | 0         |
| 313 | Basic science. , 0 , 7-24.   |     | 0         |
| 314 | Therapeutic decision making in BMT/SCT for acute myeloid leukemia. , 0 , 25-40.  |     | 0         |
| 315 | Therapeutic decision making in BMT/SCT for myelodysplasia. , 0 , 77-89.  |     | 0         |
| 316 | Therapeutic decision making in BMT/ SCT for renal cell cancer. , 0 , 146-158.  |     | 0         |
| 317 | Therapeutic decision making in BMT/SCT for severe aplastic anemia. , 0 , 165-171.  |     | 0         |
| 318 | Therapeutic decision making in BMT/SCT for congenital immunodeficiencies. , 0 , 172-178.                                 |     | 0         |
| 319 | Therapeutic decision making in BMT/SCT for hemoglobinopathies. , 0 , 179-191.  |     | 0         |
| 320 | HSCT for inborn errors of metabolism and neurodegenerative disorders. , 0 , 192-204.                                     |     | 0         |
| 321 | Therapeutic decision making in BMT/SCT for autoimmune disorders. , 0 , 205-208.  |     | 0         |
| 322 | Cellular therapy. , 0 , 209-234.   |     | 0         |
| 323 | Umbilical cord blood as an alternative allogeneic graft source: clinical banking and transplant outcomes. , 0 , 288-296. |     | 0         |
| 324 | Pathobiology of graft-versus-host disease. , 0 , 297-310.  |     | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 325 | Management and prophylaxis of infections after BMT/SCT. , 0, , 330-347.  |     | 0         |
| 326 | HLA-testing and laboratory medicine. , 0, , 509-524.   |     | 0         |
| 327 | Hematopoietic cell transplantation: past, present, and future. , 0, , 1-6.   |     | 0         |
| 328 | A Phase 1/2 Trial of Low-Dose Continuous Azacitidine in Combination with Lenalidomide and Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e262-e263.  | 0.2 | 0         |
| 329 | Roger Herschel Herzog: younger half of the dynamic duo which advanced leukaemia therapy and transplants: January 4, 1946 to July 18, 2020. <i>Leukemia</i> , 2020, 34, 2824-2825.  | 3.3 | 0         |
| 330 | AML-123: Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Engraftment in Older Patients with Active, Relapsed, or Refractory (rel/ref) AML: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 SIERRA Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S182.          | 0.2 | 0         |
| 331 | Graft-Versus-Host Disease (GvHD) Prophylaxis. , 2021, , 153-186.   |     | 0         |
| 332 | Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Older Patients with Active, Relapsed or Refractory (R/R) Acute Myeloid Leukemia Results in Successful and Timely Engraftment Not Related to the Radiation Dose Delivered. <i>Transplantation and Cellular Therapy</i> , 2021, 27, S57-S58.   | 0.6 | 0         |
| 333 | Myeloablative Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Spares the GI Tract and Has Low Incidence of Severe Mucositis, Febrile Neutropenia and Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML). <i>Transplantation and Cellular Therapy</i> , 2021, 27, S56. | 0.6 | 0         |
| 334 | Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults. <i>Blood</i> , 2008, 112, 51-51.   | 0.6 | 0         |
| 335 | Donor Characteristics Affecting Graft Failure and Survival after Unrelated Donor Transplantation with Reduced Intensity Conditioning Regimens (RIC) for Hematologic Malignancies.. <i>Blood</i> , 2008, 112, 1968-1968.  | 0.6 | 0         |
| 336 | Alternative Donor Hematopoietic Cell Transplantation (HCT) After Reduced Intensity (RIC) or Nonmyeloablative (NST) Conditioning in Advanced Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2009, 114, 3380-3380.  | 0.6 | 0         |
| 337 | Comparison of Unrelated and Sibling Donor Allogeneic Hematopoietic Cell Transplantation (HCT) for Follicular Lymphoma (FL) - From the Lymphoma Working Party, European Group for Blood and Marrow Transplantation (EBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR).. <i>Blood</i> , 2009, 114, 874-874.                                     | 0.6 | 0         |
| 338 | Monosomal Karyotype (MK) In Older Patients with Acute Myeloid Leukemia (AML) on Eastern Cooperative Oncology Group (ECOG) Therapeutic Trials: Poor Prognostic Impact of MK, but Not of Monosomy 7. <i>Blood</i> , 2010, 116, 579-579.  | 0.6 | 0         |
| 339 | CNS Remission at the Time of Autologous Stem Cell Transplantation Improves Outcome for Patients with Non-Hodgkin's Lymphoma with Pre-Existing CNS Involvement: a CIBMTR Analysis. <i>Blood</i> , 2010, 116, 371-371.   | 0.6 | 0         |
| 340 | Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study. <i>Blood</i> , 2010, 116, 680-680.  | 0.6 | 0         |
| 341 | Charlson Comorbidity Index (CCI) Not Hematopoietic Cell Transplantation Specific-Comorbidity Index (HCT-CI) Successfully Predicts Transplant Related Mortality and Post-Transplant Outcomes in Elderly Patients Undergoing Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation. <i>Blood</i> , 2011, 118, 3006-3006.                             | 0.6 | 0         |
| 342 | The Impact of Obesity on the Presentation & Outcome of Adult Acute Myeloid Leukemia (AML) - ECOG Studies E1900 & E3999. <i>Blood</i> , 2011, 118, 2568-2568.   | 0.6 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 343 | Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience. Blood, 2011, 118, 3074-3074.   | 0.6 | 0         |
| 344 | Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900,. Blood, 2011, 118, 3619-3619.   | 0.6 | 0         |
| 345 | Reduced Intensity or Non-Ablative Hematopoietic Cell Transplantation in Older Patients with Non-Hodgkin Lymphoma (NHL): Encouraging Survival for Patients ≥55 Years. Blood, 2011, 118, 1015-1015.   | 0.6 | 0         |
| 346 | BEP Versus BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Relapsed Lymphoma. A Single Center Retrospective Review of Two Contemporaneous Cohorts. Blood, 2011, 118, 2019-2019.  | 0.6 | 0         |
| 347 | O6-benzylguanine (BG) and temozolomide (TMZ) therapy of glioblastoma multiforme (GBM) with infusion of autologous lentiviral transduced P140KMGMT+ hematopoietic progenitors to protect hematopoiesis: A phase I study.. Journal of Clinical Oncology, 2012, 30, TPS1616-TPS1616. | 0.8 | 0         |
| 348 | Biology and Outcome of 85 Adults with Acute Lymphoblastic Leukemia (ALL) with t(4;11)/MLL-AF4 Treated in the UKALL XII/ECOG 2993 Study. Blood, 2012, 120, 663-663.  | 0.6 | 0         |
| 349 | Low CD34 Cell Dose Is Associated With Higher Non-Relapse and Overall Mortality After Reduced Intensity Conditioning Hematopoietic Cell Transplantation For Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2013, 122, 3342-3342.                                      | 0.6 | 0         |
| 350 | Stratification Of CLL By ZAP-70 Expression: Analysis Of Samples From The ECOG-Led Intergroup Trial E2997. Blood, 2013, 122, 4116-4116.  | 0.6 | 0         |
| 351 | Second Umbilical Cord Blood Transplant (UCBT2) In Adult Patients With Engraftment Failure Or Autologous Hematopoiesis After UCBT. Blood, 2013, 122, 2117-2117.  | 0.6 | 0         |
| 352 | Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008. Blood, 2013, 122, 63-63.  | 0.6 | 0         |
| 353 | Venous Thromboembolic Events in Diffuse Large B Cell Lymphoma. Incidence, Risk Factors and Outcomes. Blood, 2015, 126, 3968-3968.   | 0.6 | 0         |
| 354 | in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993. Blood, 2015, 126, 795-795.  | 0.6 | 0         |
| 355 | Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience. Blood, 2015, 126, 1315-1315.  | 0.6 | 0         |
| 356 | Venous Thromboembolic Events in Diffuse Large B Cell Lymphoma Patients: Risk Factors and Outcomes. Blood, 2016, 128, 3611-3611.   | 0.6 | 0         |
| 357 | Venous thromboembolism (VTE) in multiple myeloma (MM) patients undergoing autologous hematopoietic cell transplantation (HCT).. Journal of Clinical Oncology, 2017, 35, e19503-e19503.  | 0.8 | 0         |
| 358 | Relative Abundance Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Association with Transplant Outcomes. Blood, 2018, 132, 5754-5754.                                       | 0.6 | 0         |
| 359 | Diversity and Richness Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Correlation with Transplant Outcomes. Blood, 2018, 132, 4627-4627.                                   | 0.6 | 0         |
| 360 | Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia - CIBMTR Analysis. Blood, 2021, 138, 907-907.  | 0.6 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 361 | Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials. <i>Blood</i> , 2021, 138, 690-690.            | 0.6 | 0         |
| 362 | Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT). <i>Blood</i> , 2020, 136, 33-34.   | 0.6 | 0         |
| 363 | CTNI-49. PHASE I STUDY OF MGMT-P140K TRANSFECTED HEMATOPOETIC PROGENITOR CELLS COMBINED WITH TMZ/O6BG DOSE ESCALATION FOR NEWLY DIAGNOSED, UNMETHYLATED GLIOBLASTOMA: TOLERANCE AND EVIDENCE OF SURVIVAL BENEFIT. <i>Neuro-Oncology</i> , 2020, 22, ii53-ii53. | 0.6 | 0         |